Table 3 Demographic and clinical characteristics of patients included in the primary studies
Author | Year | Age (years) | Men | Mechanism | GCS | Severity |
|---|---|---|---|---|---|---|
Civil et al. [33] | 1988 | PE+31/ PE- 34 | – | Fx+: MVA100% | 15: 100% | ISS PE+11.7/PE- 8.6 |
Grant [34] | 1990 | 46, range (9–95) | 47% | TA 61% | ≥ 13: 94% | TS 15–16: 92% |
Salvino et al. [35] | 1992 | 33, range (12–78) | 66% | MVA 58% | – | ISS 11 |
Yugueros et al. [36] | 1995 | Median 33, range (14–90) | 73% | – | 15: 74% | Median ISS 8 |
SD. John et al. [37] | 1996 | 10, range (5 m– 17) | 55% | MVA 55% | – | – |
Heath et al. [38] | 1997 | Range (18– 81) | – | MVA 79% | ≥14:100% | – |
Junkins et al. [39] | 2001 | Fx+9.8/Fx-7.8 | 51% | MVA Fx+:69%/ Fx-: 54% | – | Median ISS Fx+:9/ Fx-: 8 |
Duane et al. [40] | 2002 | Fx+:3 6(17)/ Fx-:34 (19) | – | – | Fx+ 14.4 (2.1)/ Fx- 14.4 (2.1) | ISS Fx+:11.5 (7.4)/ Fx-:5.9 (6.6) |
Gonzalez et al. [41] | 2002 | 36, range (14–93) | 62% | MVA73% | ≥ 14:100% | – |
Pehle et al. [42] | 2003 | PE+: 40 (22)/ PE-: 44 (20) | 71% | – | PE+10.7 (4.8)/ PE-:10.8 (4.6) | ISS PE+42.3 (19.6)/ PE- 19.9 (15.6) |
Waydhas et al. [12] | 2007 | – | 71% | – | 9.8 (4.7) | ISS 23.3 (17.4) |
Duane et al. [43] | 2008 | Fx+: 41 (18)/ Fx-: 39 (17) | – | – | Fx+: 12.3 (4.6)/Fx-: 13.9 (3.1) | – |
Duane et al. [44] | 2009 | 34 (12) | 80% | MVA 76% | 12.8 (4.1) | – |
Shlamovitz et al. [45] | 2009 | 36 (20) | 68% | MVA 44% | 14 (2.6) | RTS 10.6 (1.5) |
Lagisetty et al. [46] | 2012 | – | – | MVA68% | < 14: 11.3% | – |
Lustenberger et al. [11] | 2016 | 43 (20) in true-positive | 66% in TP | – | 11.8 (4.4) in TP | 29.6 (14.6) in TP |
Majidinejad et al. [47] | 2018 | 32 (14) | 76% | – | – | – |
Schweigkofler et al. [48] | 2017 | 46 | 69% | TA 51% | – | – |
Leent et al. [10] | 2019 | 49(20) | 70% | TA 63% | ≤13: 46% | – |
Moosa et al. [49] | 2019 | 37(14) | 92% | – | – | – |